XSC
CRDF icon

X-Square Capital’s Cardiff Oncology CRDF Stock Holding History

X-Square Capital’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267K Buy
+205,700
New +$327K 0.07% 157
2020
Q3 		– Sell
-17,000
Closed -$85K – 98
2020
Q2 		$85K Buy
+17,000
New +$34.8K 0.06% 88

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

X-Square Capital's CRDF Position: Q2 2026 in Review

X-Square Capital opened a new position in Cardiff Oncology (CRDF) in Q2 2026: 205,700 shares worth $267K. The stake represents 0.07% of the portfolio and ranks #157 among its holdings. This is a return to the name: X-Square Capital previously reported a position in CRDF as recently as Q2 2020.

X-Square Capital first reported a position in CRDF in Q2 2020 and has held it in 2 quarters since. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • X-Square Capital held 205,700 shares of Cardiff Oncology worth $267K as of Q2 2026.
  • Cardiff Oncology was a new X-Square Capital position in Q2 2026.
  • Cardiff Oncology made up 0.07% of X-Square Capital's portfolio in Q2 2026, its #157 holding.
  • X-Square Capital first reported a position in Cardiff Oncology in Q2 2020 and has held it in 2 quarters since.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on X-Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.